Algeta developed novel targeted cancer therapies based on its alpha-pharmaceutical platform. The company’s lead product, Xofigo®, is approved in the US and Europe for skeletal metastases from prostate cancer. Algeta was Abingworth’s first VIPE (Venture Investment in Public Equity) and was acquired by Bayer for $2.9 billion in March 2014.

LocationOslo, Norway